Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design, and methodology.
Rovner ES, Carlson KV, Deal AS, Nair KV, Oakkar EE, Park J, Gemmen E, Kristy RM, Gooch KL, Schermer CR. Rovner ES, et al. Among authors: schermer cr. Contemp Clin Trials. 2018 Jul;70:83-87. doi: 10.1016/j.cct.2018.05.006. Epub 2018 May 16. Contemp Clin Trials. 2018. PMID: 29777865 Free article.
Cardiovascular risk profile in individuals initiating treatment for overactive bladder - Challenges and learnings for comparative analysis using linked claims and electronic medical record databases.
Vonesh E, Gooch KL, Khangulov V, Schermer CR, Johnston KM, Szabo SM, Rumsfeld JS. Vonesh E, et al. Among authors: schermer cr. PLoS One. 2018 Oct 16;13(10):e0205640. doi: 10.1371/journal.pone.0205640. eCollection 2018. PLoS One. 2018. PMID: 30325968 Free PMC article.
Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
Herschorn S, Staskin D, Tu LM, Fialkov J, Walsh T, Gooch K, Schermer CR. Herschorn S, et al. Among authors: schermer cr. Health Qual Life Outcomes. 2018 Apr 19;16(1):69. doi: 10.1186/s12955-018-0892-0. Health Qual Life Outcomes. 2018. PMID: 29673355 Free PMC article. Clinical Trial.
Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS).
Kaplan SA, Herschorn S, McVary KT, Staskin D, Chapple C, Foley S, Cambronero Santos J, Kristy RM, Choudhury N, Hairston J, Schermer CR. Kaplan SA, et al. Among authors: schermer cr. J Urol. 2020 Jun;203(6):1163-1171. doi: 10.1097/JU.0000000000000738. Epub 2020 Jan 2. J Urol. 2020. PMID: 31895002 Clinical Trial.
74 results